Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 151 publications
Suppression of EGFR signaling and drug-induced potentiation are widespread features of oncogenic RTK fusions.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 10, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 26, 2026
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.
Journal: Science signaling
Published: December 23, 2025
EGFR suppression and drug-induced potentiation are widespread features of oncogenic RTK fusions.
Journal: bioRxiv : the preprint server for biology
Published: December 03, 2025
Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2025
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.
Journal: Breast cancer research and treatment
Published: February 06, 2025
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK -driven lung cancer via concurrent integrin and MET signaling.
Journal: bioRxiv : the preprint server for biology
Published: September 10, 2024
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Journal: Nature medicine
Published: August 20, 2024
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer.
Journal: Clinical lung cancer
Published: July 22, 2024
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 19, 2024
Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance.
Journal: Nature communications
Published: July 06, 2024
Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression.
Journal: Thoracic cancer
Published: August 15, 2023
Last Updated: 09/26/2026